Sarepta Therapeutics and FarmaMondo announce an agreement to exclusively manage access of eteplirsen and golodirsen in Russia

December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia.

FarmaMondo SA, the world’s leader in managing paid access to unlicensed medicines announced an exclusive Distribution and Representation agreement with Sarepta Therapeutics Inc.

Under the terms of this agreement, FarmoMondo will extend its current exclusive distribution agreement for eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia.

About eteplirsen and golodirsen

Eteplirsen and golodirsen are indicated for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 51 and 53 skipping respectively. Both eteplirsen and golodirsen are manufactured and marketed by Sarepta, which is headquartered in Cambridge, Mass. They are approved via the U.S. Food and Drug Administration’s accelerated approval program under the brand names EXONDYS 51® and VYONDYS 53™.


About FarmaMondo

FarmaMondo is a Swiss-headquartered pharmaceutical group focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to facilitate patient’s access to medicines across the unlicensed and licensed product lifecycle stages. FarmaMondo support biopharmaceutical companies in their mission to extend greater access for their medicines by ethically supplying product to patients in markets where it has not been commercially launched yet.


Program Contact details

All requests must be submitted by the treating physician on behalf of the patient. Healthcare providers in Russia can obtain details about the Access Program by contacting FarmaMondo’s dedicated email address: